RimabotulinumtoxinB (Myobloc®)

Myobloc (rimabotulinumtoxinB) is covered only for FDA‑approved indications—adult (≥18) cervical dystonia and chronic sialorrhea—with off‑label use excluded. Approvals are for 12 months with dosing limits (cervical dystonia ≤5,000 units divided among affected muscles; sialorrhea ≤3,500 units divided among parotid/submandibular glands) given no more frequently than every 12 weeks, with implied documentation of diagnosis, age, doses/injection sites, and prior dosing intervals to support medical necessity.

"Treatment of adults with cervical dystonia."

Sign up to see full coverage criteria, indications, and limitations.